Update of HIV-Associated Sensory Neuropathies
- 344 Downloads
Purpose of review
HIV-sensory neuropathy (HIV-SN) remains a common complication of HIV infection and may be associated with significant morbidity due to neuropathic pain. The overall purpose of this review is to discuss trends in the changing epidemiology in HIV-SN, new data regarding the pathophysiology of the condition, and discuss approaches to management.
While HIV-SN has been historically considered the most common neurological complication of HIV infection, improved accessibility to effective combination antiretroviral therapy (cART), use of less neurotoxic antiretroviral medication regimens, and trends towards earlier introduction of treatment have impacted the condition: overall incident HIV-SN is likely decreased compared to prior rates and patients afflicted by HIV-SN may more frequently have asymptomatic or subclinical disease. Traditional predictors of HIV-SN have also changed, as traditional indices of severe immune deficiency such as low CD4 count and high viral load no longer predict HIV-SN. Emerging evidence supports the contention that both peripheral and central mechanisms underlying the generation as well as persistence of neuropathic pain in HIV-SN exist. It is important to recognize that even mild neuropathic pain in this clinical population is associated with meaningful impairment in quality of life and function, which emphasizes the clinical importance of recognizing and treating the condition. The general approach to management of neuropathic pain in HIV-SN is the introduction of symptomatic analgesic therapy. There exist, however, few evidence-based analgesic options for HIV-SN based on available clinical data. Symptomatic treatment trials are increasingly recognized to have been potentially confounded by more robust placebo response than that observed in other neuropathic pain conditions. In the authors’ experience, use of analgesic therapies with proven efficacy in other neuropathic pain conditions is appropriate, bearing in consideration potential pharmacokinetic interactions with the cART regimen. Combination analgesic regimens may also achieve meaningful analgesic responses, particularly when drugs with differing mechanisms of action are utilized. It is paramount that the patient is appropriately counseled regarding expectations and the anticipated benefit of analgesic therapy, as pain relief is often incomplete but clinically meaningful improvement in pain and function can be achieved.
KeywordsHIV Polyneuropathy Distal symmetric polyneuropathy Peripheral neuropathy Sensory neuropathy Neuropathic pain
Compliance with Ethical Standards
Conflict of Interest
Angela Aziz-Donnelly declares no potential conflicts of interest.
Taylor B. Harrison reports personal fees from Medlink.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
References and Recommended Reading
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 1.AIDSinfo. Core Epidemiology Slides. Joint United Nations Programme on HIV/AIDS, Genevea, Switzerland 2017. http://aidsinfo.unaids.org/. Accessed 12 July 2017
- 10.Ellis RJ, Rosario D, Clifford DB, McArthur JC, Simpson D, Alexander T, et al. Continued high prevalence and adverse clinical impact of human immunodeficiency virus-associated sensory neuropathy in the era of combination antiretroviral therapy: the CHARTER Study. Arch Neurol. 2010;67(5):552–8. doi: 10.1001/archneurol.2010.76.CrossRefPubMedPubMedCentralGoogle Scholar
- 11.Keltner JR, Vaida F, Ellis RJ, Moeller-Bertram T, Fitzsimmons C, Duarte NA, et al. Health-related quality of life ‘well-being’ in HIV distal neuropathic pain is more strongly associated with depression severity than with pain intensity. Psychosomatics. 2012;53(4):380–6. doi: 10.1016/j.psym.2012.05.002.CrossRefPubMedPubMedCentralGoogle Scholar
- 26.• Lee AJ, Bosch RJ, Evans SR, Wu K, Harrison T, Grant P, et al. Patterns of peripheral neuropathy in ART-naive patients initiating modern ART regimen. J Neuro-Oncol. 2015;21(2):210–8. doi: 10.1007/s13365-015-0327-1. This study suggests that, amongst patient treated with current antiretroviral regimens, the frequency of symptomatic HIV-SN may decrease.Google Scholar
- 27.Department of Health and Human Services. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. In AIDSInfo. https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-treatment-guidelines/0/. Accessed 14 July 2016.
- 28.Malvar J, Vaida F, Sanders CF, Atkinson JH, Bohannon W, Keltner J, et al. Predictors of new-onset distal neuropathic pain in HIV-infected individuals in the era of combination antiretroviral therapy. Pain. 2015;156(4):731–9. doi: 10.1097/01.j.pain.0000461252.75089.bf.CrossRefPubMedPubMedCentralGoogle Scholar
- 37.Lakritz JR, Thibault DM, Robinson JA, Campbell JH, Miller AD, Williams KC, et al. alpha4-integrin antibody treatment blocks monocyte/macrophage traffic to, vascular cell adhesion molecule-1 expression in, and pathology of the dorsal root ganglia in an SIV macaque model of HIV-peripheral neuropathy. Am J Pathol. 2016;186(7):1754–61. doi: 10.1016/j.ajpath.2016.03.007.CrossRefPubMedPubMedCentralGoogle Scholar
- 38.• Lakritz JR, Yalamanchili S, Polydefkis MJ, Miller AD, McGrath MS, Williams KC, et al. An oral form of methylglyoxal-bis-guanylhydrazone reduces monocyte activation and traffic to the dorsal root ganglia in a primate model of HIV-peripheral neuropathy. J Neuro-Oncol. 2017; doi: 10.1007/s13365-017-0529-9. This study suggests that macrophages play an important role in HIV-SN pathology at the level of the dorsal root ganglia.
- 47.Cherry CL, Rosenow A, Affandi JS, McArthur JC, Wesselingh SL, Price P. Cytokine genotype suggests a role for inflammation in nucleoside analog-associated sensory neuropathy (NRTI-SN) and predicts an individual’s NRTI-SN risk. AIDS Res Hum Retrovir. 2008;24(2):117–23. doi: 10.1089/aid.2007.0168.CrossRefPubMedGoogle Scholar
- 51.• Keltner JR, Fennema-Notestine C, Vaida F, Wang D, Franklin DR, Dworkin RH, et al. HIV-associated distal neuropathic pain is associated with smaller total cerebral cortical gray matter. J Neuro-Oncol. 2014;20(3):209–18. doi: 10.1007/s13365-014-0236-8. This study suggests that central mechanisms may be important in the pathophysiology of neuropathic pain in HIV-SN.Google Scholar
- 52.• Keltner JR, Connolly CG, Vaida F, Jenkinson M, Fennema-Notestine C, Archibald S, et al. HIV distal neuropathic pain is associated with smaller ventral posterior cingulate cortex. Pain Med. 2017;18(3):428–40. doi: 10.1093/pm/pnw180. This study further implicates central nervous system pathology as a contributor to HIV-SN neuropathic pain.PubMedGoogle Scholar
- 55.Youle M, Osio M. A double-blind, parallel-group, placebo-controlled, multicentre study of acetyl L-carnitine in the symptomatic treatment of antiretroviral toxic neuropathy in patients with HIV-1 infection. HIV Med. 2007;8(4):241–50. doi: 10.1111/j.1468-1293.2007.00467.x.CrossRefPubMedGoogle Scholar
- 57.Evans SR, Simpson DM, Kitch DW, King A, Clifford DB, Cohen BA, et al. A randomized trial evaluating prosaptide for HIV-associated sensory neuropathies: use of an electronic diary to record neuropathic pain. PLoS One. 2007;2(6):e551. doi: 10.1371/journal.pone.0000551.CrossRefPubMedPubMedCentralGoogle Scholar
- 60.Shikuma CM, Bennett K, Ananworanich J, Gerschenson M, Teeratakulpisarn N, Jadwattanakul T, et al. Distal leg epidermal nerve fiber density as a surrogate marker of HIV-associated sensory neuropathy risk: risk factors and change following initial antiretroviral therapy. J Neuro-Oncol. 2015;21(5):525–34. doi: 10.1007/s13365-015-0352-0.Google Scholar
- 61.Phillips TJ, Cherry CL, Cox S, Marshall SJ, Rice AS. Pharmacological treatment of painful HIV-associated sensory neuropathy: a systematic review and meta-analysis of randomised controlled trials. PLoS One. 2010;5(12):e14433. doi: 10.1371/journal.pone.0014433.CrossRefPubMedPubMedCentralGoogle Scholar
- 64.•• Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron R, Dworkin RH, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015;14(2):162–73. doi: 10.1016/S1474-4422(14)70251-0. A systematic review of randomized double-blind studies investigating the efficacy of oral and topical therapies for the treatment of neuropathic pain which proposes important recommendations for therapeutic treatment options.CrossRefPubMedPubMedCentralGoogle Scholar
- 66.Shlay JC, Chaloner K, Max MB, Flaws B, Reichelderfer P, Wentworth D, et al. Acupuncture and amitriptyline for pain due to HIV-related peripheral neuropathy: a randomized controlled trial. Terry Beirn Community Programs for Clinical Research on AIDS. JAMA. 1998;280(18):1590–5.CrossRefPubMedGoogle Scholar
- 78.Harrison T, Miyahara S, Lee A, Evans S, Bastow B, Simpson D, et al. Experience and challenges presented by a multicenter crossover study of combination analgesic therapy for the treatment of painful HIV-associated polyneuropathies. Pain Med. 2013;14(7):1039–47. doi: 10.1111/pme.12084.CrossRefPubMedPubMedCentralGoogle Scholar
- 82.Chou R, Fanciullo GJ, Fine PG, Miaskowski C, Passik SD, Portenoy RK. Opioids for chronic noncancer pain: prediction and identification of aberrant drug-related behaviors: a review of the evidence for an American Pain Society and American Academy of Pain Medicine clinical practice guideline. J Pain. 2009;10(2):131–46. doi: 10.1016/j.jpain.2008.10.009.CrossRefPubMedGoogle Scholar
- 83.•• Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain—United States, 2016. JAMA. 2016;315(15):1624–45. doi: 10.1001/jama.2016.1464. An important guideline for clinicians caring for patients with HIV-SN for whom opioid therapy is either current or considered.CrossRefPubMedGoogle Scholar